Human Erythropoietin (hEPO)

• 产品编号：CST-6980LF      品牌：CST       原厂货号：6980LF
• 产品分类：蛋白质检测与分析 > 蛋白质，多肽和酶 > 细胞因子和生长因子 > 其它细胞因子和生长因子
• 应用分类：

描述：

CST公司生产的人重组蛋白Erythropoietin (hEPO) Ala28-Arg193 (Accession #NP_000790)是从人源293细胞表达而来。重组的hEPO蛋白在N-末端没有标签，未糖基化蛋白分子量据推算为20,417Da。DTT-还原蛋白和未还原蛋白作为34-40 kDa的蛋白转移。在SDS-PAGE中稍低的迁移率是由于糖基化。重组hEPO蛋白的N-末端APPRL的序列通过测序得到。6 μg 还原 (+) 和 非还原的(-) 重组hEPO通过SDS-PAGE检测，纯度大于98%，所有批次的纯度均高于98%。hEPO的生物活性是通过TF-1细胞增殖来确定的。每个批次的ED50在50-400 pg/ml之间。

有载体: 每微克hEPO蛋白溶解在包含 20 μg BSA的PBS（pH 7.2）溶液中，并通过 0.22 μm 滤膜冻干。

无载体：每微克hEPO蛋白溶解在PBS（pH 7.2）溶液中，并通过 0.22 μm 滤膜冻干。

EPO是一个34 kDa 蛋白，是红细胞生存和终止分化所必需的(1)。EPO能够被包括管内皮细胞、间质细胞、肝细胞、Kupffer细胞、星形胶质细胞和Schwann细胞的很多细胞产生(2-4)。EPO抑制凋亡并能够保护神经细胞因缺血引起的和神经退化疾病过程中的死亡(3,4)。EPO通过抑制 NF-κB信号通路而抑制促炎症因子的产生(5)。 在动物模型中，EPO通过促进胰腺β细胞的生存和生长而抑制肥胖的发展(6)。EPO结合到其同系物受体EPOR上诱导Jak2, Stat5 和Akt的激活(3-5)。

原厂资料：

Source / Purification

Recombinant human Erythropoietin (hEPO) Ala28-Arg193 (Accession #NP_000790) was expressed in human 293 cells at Cell Signaling Technology.

Molecular Characterization

Recombinant hEPO contains no "tags" and the nonglycosylated protein has a calculated MW of 20,417. DTT-reduced and non-reduced protein migrate as 34-40 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation. The expected amino-terminal APPRL of recombinant hEPO was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hEPO. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant hEPO was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 50-400 pg/ml.

Endotoxin

Less than 0.01 ng endotoxin/1μg hEPO.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hEPO. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

Background

EPO is a 34 kDa protein that is required for the survival and terminal differentiation of erythrocytes (1). EPO is produced by a number of cell types including tubular endothelial cells, interstitial cells, hepatocytes, Kupffer cells, astrocytes, and Schwann cells (2-4). EPO inhibits apoptosis and may protect neuronal cells from death during ischemia and/or neurodegenerative diseases (3,4). EPO inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling (5). EPO protected against the development of diabetes in an animal model by promoting pancreatic β cell survival and growth (6). Binding of EPO to its cognate receptor, EPOR, induces activation of Jak2, Stat5 and Akt (3-5).

注意事项：

Storage: Stable in lyophilized state at 4ºC for 1 year after
receipt. Sterile stock solutions reconstituted with carrier protein
are stable at 4ºC for 2 months and at -20ºC for 6 months. Avoid
repeated freeze-thaw cycles.